About Adagene
Adagene is a publicly listed company based in Suzhou (China) founded in 2012 by Peter Luo. Immunotherapy antibodies for cancer treatment are developed. Adagene has raised $155 million across 5 funding rounds from investors including WuXi AppTec, General Atlantic and Sanofi. The company has 138 employees. Its chief executive, as recorded, is Peter Luo. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ADAGENE INCORPORATED.
Company details
Adagene was founded in 2012 in Suzhou, China, and operates in the biotechnology sector focused on cancer immunotherapy. Antibodies are developed, including ADG106 as an agonist for CD137 in metastatic solid tumors, ADG126 targeting CTLA4 for cancer therapy, and ADG116 targeting a CTLA4 epitope in metastatic solid tumors and relapsedrefractory non-Hodgkins lymphoma. Operations center on advancing these therapies for oncology applications.
- Headquarters Suzhou, China
- Employees 138
- Founders Peter Luo
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website adagene.com
- Social LinkedIn
- Legal Name Adagene, Inc. Sponsored Adr
- Annual Revenue$7.69 M (USD)7348.68as on Dec 31, 2025
- Net Profit-$17.66 M (USD)47.2as on Dec 31, 2025
- EBITDA-$20.91 M (USD)40.32as on Dec 31, 2025
- Total Equity Funding$155M (USD)
in 5 rounds
- Latest Funding Round$25M (USD), Post-IPO
Jul 2025
- InvestorsWuXi AppTec
& 12 more
- Employee Count138
Funding Insights of Adagene
Adagene has successfully raised a total of $155M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $155M
- Total Rounds 5
- Last Round Post-IPO — $25M
- First Round $8M
(Dec 2014)
- Investors Count 13
All 5 funding rounds of Adagene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $25M | Post-IPO | – | – | |
| Jan 2020 | $69M | Series D | – | General Atlantic | |
| Mar 2018 | $50M | Series C | – | Sequoia Capital | |
| Jan 2016 | $28M | Series B | – | F-Prime Capital, Eight Roads Ventures | |
| Dec 2014 | $8M | Series A | – | F-Prime Capital, Eight Roads Ventures | – |
13 investors in total: 13 institutional.
Investors in Adagene
Adagene has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include WuXi AppTec, General Atlantic and Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Investments are provided by GP Capital to financial services companies. | gpcapital.com.cn | Shanghai, China | ||
| nwtmt.com | ||||
Offers financial advisory services, including planning, analysis, and wealth management. | 2009 | avictc.com | Nanchang, China | |
| gopherasset.com | ||||
Provider of CRO and CDMO services | 2000 | wuxiapptec.com | Shanghai, China |
Investor details for Adagene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adagene
23 people are tracked at Adagene (17 in leadership, 6 in board & advisors); the tracked headcount is 138.
| Name | Role | Group |
|---|---|---|
Peter Luo | Founder & CEO | Leadership |
JC Xu | Chief Strategy Officer And Head Of Regulatory Affairs | Leadership |
Qinghai Zhao | Chief Manufacturing Officer | Leadership |
Guizhong Liu | Sr. Vp, Early Drug Discovery | Leadership |
Alexander Goergen | Head Of Business Development | Leadership |
Yan Li | VP Of Bioinformatics & IT | Leadership |
Dana Hu-Lowe | Vp, Global Project Team Leadhersip And Clinical Programs Management | Leadership |
Songmao Zheng | Senior Vice President Of Clinical Pharmacology And Quantitative Sciences | Leadership |
Jiping Zha | Executive Vice President, Clinical Development | Leadership |
Kristine She | SVP, Head of Clinical Operations | Leadership |
Wenlin Zeng | VP, Early Stage CMC | Leadership |
Ami Celeste Knoefler | VP, Investor Relations & Corporate Communications | Leadership |
Meiling Dai | Senior Director Of Corporate Development, CFA Charterholder | Leadership |
Man Kin Tam | Chief Financial Officer & Director | Leadership |
Chunfang Gu | Senior Director of Finance | Leadership |
Ling Zhou | Head of Human Resources | Leadership |
Aaron N. Nguyen | Executive Director, Translational Sciences And Partnered Programs | Leadership |
Zhu Li | Independent Director | Board & advisors |
Andy Cheung | Independent Director | Board & advisors |
Yumeng Wang | Director | Board & advisors |
3 more people are available in the full profile.
Complete people profiles for Adagene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Adagene
Adagene is a publicly listed company on the NASDAQ with ticker symbol ADAG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Feb 2021
- Listed onNASDAQ: ADAG
- Listed entityAdagene, Inc. Sponsored ADR
- Exchange sectorHealth technology
- ISINUS0053291078
- Share price$2.46 (-10.22% on the day) · 2026-10-13
- Market capitalisation$165.2M
- EPS (diluted, trailing year)$-0.38
- Volume (last session)228,888
Financials of Adagene
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $7.7M | -$17.7M | -$20.9M |
| 2024 | $103,260 | -$33.4M | -$35.0M |
| 2023 | $18.1M | -$18.9M | -$26.0M |
| 2022 | $9.3M | -$79.9M | -$82.4M |
| 2021 | $10.2M | -$73.3M | -$71.3M |
Detailed financial statements for Adagene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Adagene
4 dated milestones of Adagene across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Adagene is founded.
- Funding First funding round of $8.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
Web traffic of Adagene
The website of Adagene (adagene.com) receives about 3.1K visits a month and ranks #7,260,750 among all websites worldwide, #6,958 in Biotechnology and Pharmaceuticals.
- Monthly visits3.1K
▲ 42.2% vs previous month
- Global rank#7,260,750
among all websites
- Category rank#6,958
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit29 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Adagene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
oncodaily.com | oncodaily.com | 100% | #147,518 | – | |
futureprize.org | futureprize.org | 53% | #2,703,251 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adagene
Complete news archive for Adagene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adagene
Adagene was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Adagene is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Peter Luo is the CEO of Adagene, as recorded in our data. They have also founded this company.
Adagene is a funded company, having raised a total of $155M across 5 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Dec 2014.
Adagene has 138 employees.
Annual revenue of Adagene is $7.69M as on Dec 31, 2025.
Adagene was founded in 2012 in Suzhou, China, and operates in the biotechnology sector focused on cancer immunotherapy. Antibodies are developed, including ADG106 as an agonist for CD137 in metastatic solid tumors, ADG126 targeting CTLA4 for cancer therapy, and ADG116 targeting a CTLA4 epitope in metastatic solid tumors and relapsedrefractory non-Hodgkins lymphoma. Operations center on advancing these therapies for oncology applications.
Yes, Adagene is publicly traded on NASDAQ under the ticker symbol ADAG.
Adagene has 13 investors. Key investors include WuXi AppTec, General Atlantic, Sanofi, Fidelity International, and Eight Roads Ventures.
Adagene operates through Adagene Incorporated.